In other studies, lower E-cadherin expression was associated with a larger tumor size [31], a more advanced CRC stage at diagnosis, a tendency toward lymph node involvement [33], lymphovascular and perineural invasion [15], a worse clinical response to treatment [34], more frequent recurrences, shorter 5-year disease-free survival [35], shorter 10-year survival [36], and a worse response to neoadjuvant therapy [37]. This evidence concerns the gene CDH1 and neoplasm.